American Shared Hospital Services (AMS) 10-Q 15 May 17 2017 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2017	May 05, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Entity Registrant Name	AMERICAN SHARED HOSPITAL SERVICES
Entity Central Index Key	744,825
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	AMS
Entity Common Stock, Shares Outstanding		5,707,000

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2017	Dec. 31, 2016
CURRENT ASSETS
Cash and cash equivalents	$ 2,403,000	$ 2,871,000
Restricted cash	250,000	250,000
Accounts receivable, net of allowance for doubtful accounts of $100,000 at March 31, 2017 and $100,000 at December 31, 2016	4,881,000	4,085,000
Other receivables	249,000	290,000
Prepaid expenses and other current assets	982,000	892,000
Total current assets	8,765,000	8,388,000
Property and equipment:
Medical equipment and facilities	98,490,000	96,270,000
Office equipment	537,000	537,000
Deposits and construction in progress	6,959,000	8,073,000
Property and equipment	105,986,000	104,880,000
Accumulated depreciation and amortization	(55,160,000)	(53,549,000)
Net property and equipment	50,826,000	51,331,000
Investment in equity securities	579,000	579,000
Other assets	263,000	300,000
Total assets	60,433,000	60,598,000
CURRENT LIABILITIES
Accounts payable	437,000	319,000
Employee compensation and benefits	193,000	184,000
Other accrued liabilities	1,103,000	1,100,000
Current portion of long-term debt	2,215,000	2,205,000
Current portion of obligations under capital leases	4,490,000	4,873,000
Total current liabilities	8,438,000	8,681,000
Long-term debt, less current portion	5,597,000	5,106,000
Long-term capital leases, less current portion	13,691,000	14,852,000
Deferred revenue, less current portion	583,000	610,000
Deferred income taxes	4,350,000	4,176,000
Shareholders' equity:
Common stock (10,000,000 authorized; 5,706,000 shares issued and outstanding at March 31, 2017 and 5,468,000 at December 31, 2016)	10,711,000	10,596,000
Additional paid-in capital	5,999,000	5,949,000
Retained earnings	5,243,000	4,950,000
Total equity- American Shared Hospital Services	21,953,000	21,495,000
Non-controlling interests in subsidiaries	5,821,000	5,678,000
Total shareholders' equity	27,774,000	27,173,000
Total liabilities and shareholders' equity	$ 60,433,000	$ 60,598,000

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Allowance for doubtful accounts (in dollars)	$ 100,000	$ 100,000
Common stock, shares authorized	10,000,000	10,000,000
Common stock, shares issued	5,706,000	5,468,000
Common stock, shares outstanding	5,706,000	5,468,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenue:
Medical services revenue	$ 4,914,000	$ 4,238,000
Costs of revenue:
Maintenance and supplies	232,000	244,000
Depreciation and amortization	1,604,000	1,562,000
Other direct operating costs	732,000	699,000
Costs of revenue	2,568,000	2,505,000
Gross margin	2,346,000	1,733,000
Selling and administrative expense	1,139,000	949,000
Interest expense	453,000	285,000
Operating income	754,000	499,000
(Loss) on early extinguishment of debt	0	(108,000)
Interest and other income	4,000	5,000
Income before income taxes	758,000	396,000
Income tax expense	216,000	64,000
Net income	542,000	332,000
Less: net income attributable to non-controlling interests	(249,000)	(281,000)
Net income attributable to American Shared Hospital Services	$ 293,000	$ 51,000
Net income per share:
Earnings per common share - basic	$ 0.05	$ 0.01
Earnings per common share - diluted	$ 0.05	$ 0.01

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Sub-Total ASHS [Member]	Non-controlling Interest [Member]
Balances at Dec. 31, 2015	$ 25,180,000	$ 10,376,000	$ 5,734,000	$ 4,020,000	$ 20,130,000	$ 5,050,000
Balances (in shares) at Dec. 31, 2015		5,364,000
Stock based compensation expense	215,000	$ 0	215,000	0	215,000	0
Stock based compensation expense (in shares)		4,000
Warrants and options exercised	220,000	$ 220,000	0	0	220,000	0
Warrants and options exercised (in shares)		100,000
Non-controlling interest investment in subsidiaries	7,000	$ 0	0	0	0	7,000
Cash distributions to non-controlling interests	(699,000)	0	0	0	0	(699,000)
Net income	2,250,000	0	0	930,000	930,000	1,320,000
Balances at Dec. 31, 2016	27,173,000	$ 10,596,000	5,949,000	4,950,000	21,495,000	5,678,000
Balances (in shares) at Dec. 31, 2016		5,468,000
Stock based compensation expense	50,000	$ 0	50,000	0	50,000	0
Stock based compensation expense (in shares)		0
Restricted stock	$ 0	$ 0	0	0	0	0
Restricted stock (in shares)		162,000
Warrants and options exercised (in shares)	100,000
Stock Issued During Period, Value, Stock Options Exercised	$ 115,000	$ 115,000	0	0	115,000	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		76,000
Cash distributions to non-controlling interests	(106,000)	$ 0	0	0	0	(106,000)
Net income	542,000	0	0	293,000	293,000	249,000
Balances at Mar. 31, 2017	$ 27,774,000	$ 10,711,000	$ 5,999,000	$ 5,243,000	$ 21,953,000	$ 5,821,000
Balances (in shares) at Mar. 31, 2017		5,706,000

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
OPERATING ACTIVITIES
Net income	$ 542,000	$ 332,000
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	1,622,000	1,574,000
(Gain) on sale of assets	0	(1,000)
Loss on early extinguishment of debt	0	108,000
Deferred income tax	174,000	64,000
Stock-based compensation expense	50,000	59,000
Net accrued interest on lease financing	(27,000)	0
Other non-cash items	0	4,000
Changes in operating assets and liabilities:
Receivables	(755,000)	(500,000)
Prepaid expenses and other assets	(60,000)	22,000
Customer deposits/deferred revenue	(31,000)	(78,000)
Accounts payable and accrued liabilities	134,000	136,000
Net cash from operating activities	1,649,000	1,720,000
Investing activities:
Payment for purchase of property and equipment	(1,106,000)	(333,000)
Net cash used in investing activities	(1,106,000)	(333,000)
Financing activities:
Principal payments on long-term debt	(495,000)	(1,439,000)
Principal payments on capital leases	(1,517,000)	(1,064,000)
Proceeds from long-term debt financing on property and equipment	992,000	0
Capital contributions from non-controlling interests	0	7,000
Distributions to non-controlling interests	(106,000)	(97,000)
Proceeds from warrants and options exercised	115,000	0
Proceeds from capital lease financing for reimbursement of payments for acquisition of equipment	0	1,137,000
Net cash used in financing activities	(1,011,000)	(1,456,000)
Net change in cash and cash equivalents	(468,000)	(69,000)
Cash and cash equivalents at beginning of period	2,871,000	2,209,000
Cash and cash equivalents at end of period	2,403,000	2,140,000
Supplemental cash flow disclosure:
Interest	491,000	515,000
Income taxes	22,000	96,000
Schedule of non-cash investing and financing activities
Acquisition of equipment with capital lease financing	$ 0	$ 6,870,000

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Basis of Presentation In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of only normal recurring accruals) necessary to present fairly American Shared Hospital Services’ consolidated financial position as of March 31, 2017 and the results of its operations for the three month periods ended March 31, 2017 and 2016, which results are not necessarily indicative of results on an annualized basis. Consolidated balance sheet amounts as of December 31, 2016 have been derived from audited consolidated financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2016 included in the Company’s 10-K filed with the Securities and Exchange Commission. These consolidated financial statements include the accounts of American Shared Hospital Services and its subsidiaries (the “Company”) as follows: the Company wholly-owns the subsidiaries American Shared Radiosurgery Services (“ASRS”), PBRT Orlando, LLC (“Orlando”), OR21, Inc. (“OR21”), and MedLeader.com, Inc. (“MedLeader”); the Company is the majority owner of Long Beach Equipment, LLC (“LBE”); ASRS is the majority-owner of GK Financing, LLC (“GKF”) which wholly-owns the subsidiaries Instituto de Gamma Knife del Pacifico S.A.C. (“GKPeru”) and GK Financing U.K., Limited (“GKUK”); GKF is the majority owner of the subsidiaries Albuquerque GK Equipment, LLC (“AGKE”) and Jacksonville GK Equipment, LLC (“JGKE”). The Company (through ASRS) and Elekta AB, the manufacturer of the Gamma Knife (through its wholly-owned United States subsidiary, GKV Investments, Inc.), entered into an operating agreement and formed GK Financing, LLC. During 2017 GKF provided Gamma Knife units to seventeen medical centers in the United States in the states of Arkansas, California, Connecticut, Florida, Illinois, Massachusetts, Mississippi, Nevada, New Jersey, New Mexico, New York, Tennessee, Oklahoma, Ohio, Oregon, and Texas. The Company through its wholly-owned subsidiary, Orlando, provided proton beam radiation therapy (“PBRT”) and related equipment to a customer in the United States. The Company also directly provides radiation therapy and related equipment, including Intensity Modulated Radiation Therapy (“IMRT”), Image Guided Radiation Therapy (“IGRT”) and a CT Simulator to the radiation therapy department at an existing Gamma Knife site in Massachusetts. The Company formed the subsidiaries GKPeru and GKUK for the purposes of expanding its business internationally into Peru and the United Kingdom, respectively; Orlando and LBE to provide proton beam therapy services in Orlando, Florida and Long Beach, California; and AGKE and JGKE to provide Gamma Knife services in Albuquerque, New Mexico and Jacksonville, Florida, respectively. AGKE began operations in the second quarter of 2011 and JGKE began operations in the fourth quarter of 2011. Orlando treated its first patient in April 2016. GKPeru is expected to begin operations in the third quarter of 2017. GKUK is inactive and LBE is not expected to generate revenue within the next two years. The Company continues to develop its design and business model for “The Operating Room for the 21st Century” SM SM 50 50 MedLeader was formed to provide continuing medical education online and through videos for doctors, nurses, and other healthcare workers. This subsidiary is not operational at this time. All significant intercompany accounts and transactions have been eliminated in consolidation. Based on the guidance provided in accordance with ASC 280 Segment Reporting In February 2016, the Company used proceeds from the lease financing of its MEVION S250 at UF Health Cancer Center at Orlando Health (“Orlando Health”) to pay down $ 1,000,000 Extinguishment of Liabilities Debt Modifications and Extinguishments 108,000 145,000 80,000 28,000 In July 2016, an existing customer provided notice of its intent to exercise the option to purchase the Gamma Knife unit at its hospital at the end of the lease term for a predetermined purchase price, pursuant to the lease agreement. The lease terminated in April 2017, at which time, the unit was depreciated to the purchase price of the sale. Based on the guidance provided in ASC 360 Property, Plant and Equipment As of December 31, 2016, the Company had warrants outstanding representing the right to purchase 100,000 2.20 100,000 50,000 25,000 In May 2014, the Financial Accounting Standards Board “(FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers Technical Corrections and Improvements to Topic 606, In January 2016, the FASB issued ASU No. 2016-01 Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU No. 2016-02 Leases In March 2016, the FASB issued ASU No. 2016-09 Compensation – Stock Compensation In June 2016, the FASB issued ASU No. 2016-13 Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In August 2016, the FASB issued ASU No. 2016-15 Statement of Cash Flows (Topic 230) – Classification of Certain Cash Receipts and Cash Payments In November 2016, the FASB issued ASU No. 2016-18 Statement of Cash Flows (Topic 230) – Restricted Cash

Per Share Amounts

Per Share Amounts	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 2. Per Share Amounts Per share information has been computed based on the weighted average number of common shares and dilutive common share equivalents outstanding. The computation for the three month periods ended March 31, 2017 and 2016 excluded approximately 0 617,000 Based on the guidance provided in accordance with ASC 260 Earnings Per Share Three Months ended March 31, 2017 2016 Net income attributable to American Shared Hospital Services $ 293,000 $ 51,000 Weighted average common shares for basic earnings per share 5,685,000 5,541,000 Diluted effect of stock options and restricted stock 199,000 - Weighted average common shares for diluted earnings per share 5,884,000 5,541,000 Basic earnings per share $ 0.05 $ 0.01 Diluted earnings per share $ 0.05 $ 0.01

Stock-based Compensation

Stock-based Compensation	3 Months Ended
	Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Note 3. Stock-based Compensation In June 2010 shareholders approved an amendment and restatement of the Company’s stock incentive plan, renaming it the Incentive Compensation Plan (the “Plan”), and among other things, increasing the number of shares of the Company’s common stock reserved for issuance under the Plan to 1,630,000 Stock-based compensation expense associated with the Company’s stock-based options to employees is calculated using the Black-Scholes valuation model. The Company’s stock-based awards have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value estimates. The estimated fair value of the Company’s option grants is estimated using assumptions for expected life, volatility, dividend yield, and risk-free interest rate which are specific to each award. The estimated fair value of the Company’s options is amortized over the period during which an employee is required to provide service in exchange for the award (requisite service period), usually the vesting period. Accordingly, stock-based compensation cost before income tax effect for the Company’s options and restricted stock units in the amount of $ 50,000 59,000 356,000 On January 4, 2017, the Company entered into a Performance Share Award Agreement (the “Agreements”) with three executive officers of the Company for 161,766 Stock Compensation 542,000 Restricted Grant Date Intrinsic Outstanding at January 1, 2017 4,000 $ 2.25 $ - Granted 18,000 $ 3.40 $ - Vested (4,000) $ 3.40 $ - Forfeited - $ - $ - Outstanding at March 31, 2017 18,000 $ 3.21 $ 20,000 Stock Grant Date Weighted- Outstanding at January 1, 2017 625,000 $ 2.85 4.25 Granted - $ - - Exercised (2,000) $ 2.81 - Forfeited - $ - - Outstanding at March 31, 2017 623,000 $ 2.85 4.02 Exercisable at March 31, 2017 304,000 $ 2.83 3.80

Investment in Equity Securities

Investment in Equity Securities	3 Months Ended
	Mar. 31, 2017
Investments, All Other Investments [Abstract]
Cost-method Investments, Description [Text Block]	Note 4. Investment in Equity Securities As of March 31, 2017 and December 31, 2016 the Company had a $ 579,000 0.46 The Company reviewed this investment at March 31, 2017 in light of both current market conditions and the current operations of Mevion as they continue to grow their PBRT business. Based on its analysis, the Company determined no impairment needed to be recognized as of March 31, 2017.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	Note 5. Fair Value of Financial Instruments The Company’s disclosures of the fair value of financial instruments is based on a fair value hierarchy which prioritizes the inputs to the valuation techniques used to measure fair value into three levels. Level 1 inputs are unadjusted quoted market prices in active markets for identical assets and liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for assets or liabilities, and reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the asset or liability. The estimated fair value of the Company’s assets and liabilities as of March 31, 2017 and December 31, 2016 were as follows (in thousands): Level 1 Level 2 Level 3 Total Carrying Value March 31, 2017 Assets: Cash, cash equivalents, restricted cash $ 2,653 $ - $ - $ 2,653 $ 2,653 Investment in equity securities - - 579 579 579 Total $ 2,653 $ - $ 579 $ 3,232 $ 3,232 Liabilities Debt obligations $ - $ - $ 7,040 $ 7,040 $ 7,812 Total $ - $ - $ 7,040 $ 7,040 $ 7,812 December 31, 2016 Assets: Cash, cash equivalents, restricted cash $ 3,121 $ - $ - $ 3,121 $ 3,121 Investment in equity securities - - 579 579 579 Total $ 3,121 $ - $ 579 $ 3,700 $ 3,700 Liabilities Debt obligations $ - $ - $ 7,354 $ 7,354 $ 7,311 Total $ - $ - $ 7,354 $ 7,354 $ 7,311

Repurchase of Common Stock

Repurchase of Common Stock	3 Months Ended
	Mar. 31, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 6. Repurchase of Common Stock In 1999 and 2001, the Board of Directors approved resolutions authorizing the Company to repurchase up to a total of 1,000,000 shares of its own stock on the open market, which the Board of Directors reaffirmed in 2008. There were no shares repurchased during the three month period ended March 31, 2017 or 2016. There are approximately 72,000 shares remaining under this repurchase authorization as of March 31, 2017.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 7. Income Taxes We generally calculate our effective income tax rate at the end of an interim period using an estimate of the annualized effective income tax rate expected to be applicable for the full fiscal year. However, when a reliable estimate of the annualized effective income tax rate cannot be made, we compute our provision for income taxes using the actual effective income tax rate for the results of operations reported within the year-to-date periods. Our effective income tax rate is highly influenced by relative income or losses reported and the amount of the nondeductible stock-based compensation associated with grants of our common stock options and historically from the results of foreign operations. A small change in estimated annual pretax income (loss) can produce a significant variance in the annualized effective income tax rate given the expected amount of these items. As a result, we have computed our provision for income taxes for the three month periods ended March 31, 2017 and 2016 by applying the actual effective tax rates to income reported within the condensed consolidated financial statements through those periods.

Per Share Amounts (Tables)

Per Share Amounts (Tables)	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following table sets forth the computation of basic and diluted earnings per share for the three month periods ended March 31, 2017 and 2016: Three Months ended March 31, 2017 2016 Net income attributable to American Shared Hospital Services $ 293,000 $ 51,000 Weighted average common shares for basic earnings per share 5,685,000 5,541,000 Diluted effect of stock options and restricted stock 199,000 - Weighted average common shares for diluted earnings per share 5,884,000 5,541,000 Basic earnings per share $ 0.05 $ 0.01 Diluted earnings per share $ 0.05 $ 0.01

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]	The following table summarizes unvested restricted stock awards, consisting primarily of annual automatic grants and deferred compensation to non-employee directors, for the three-month period ended March 31, 2017: Restricted Grant Date Intrinsic Outstanding at January 1, 2017 4,000 $ 2.25 $ - Granted 18,000 $ 3.40 $ - Vested (4,000) $ 3.40 $ - Forfeited - $ - $ - Outstanding at March 31, 2017 18,000 $ 3.21 $ 20,000
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes stock option activity for the three month period ended March 31, 2017: Stock Grant Date Weighted- Outstanding at January 1, 2017 625,000 $ 2.85 4.25 Granted - $ - - Exercised (2,000) $ 2.81 - Forfeited - $ - - Outstanding at March 31, 2017 623,000 $ 2.85 4.02 Exercisable at March 31, 2017 304,000 $ 2.83 3.80

Fair Value of Financial Instr16

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The estimated fair value of the Company’s assets and liabilities as of March 31, 2017 and December 31, 2016 were as follows (in thousands): Level 1 Level 2 Level 3 Total Carrying Value March 31, 2017 Assets: Cash, cash equivalents, restricted cash $ 2,653 $ - $ - $ 2,653 $ 2,653 Investment in equity securities - - 579 579 579 Total $ 2,653 $ - $ 579 $ 3,232 $ 3,232 Liabilities Debt obligations $ - $ - $ 7,040 $ 7,040 $ 7,812 Total $ - $ - $ 7,040 $ 7,040 $ 7,812 December 31, 2016 Assets: Cash, cash equivalents, restricted cash $ 3,121 $ - $ - $ 3,121 $ 3,121 Investment in equity securities - - 579 579 579 Total $ 3,121 $ - $ 579 $ 3,700 $ 3,700 Liabilities Debt obligations $ - $ - $ 7,354 $ 7,354 $ 7,311 Total $ - $ - $ 7,354 $ 7,354 $ 7,311

Basis of Presentation (Details

Basis of Presentation (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Feb. 29, 2016	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Basis Of Presentation [Line Items]
Gain (Loss) on Extinguishment of Debt		$ 0	$ (108,000)
Warrants Issued With cashless exercise during period		25,000
Class of Warrant or Right, Outstanding				100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 2.20
Stock Issued During Period, Shares, Warrants Exercised		100,000
Notes Payable [Member]
Basis Of Presentation [Line Items]
Gain (Loss) on Extinguishment of Debt				$ 108,000
Warrants Not Settleable in Cash, Fair Value Disclosure				145,000
Debt Instrument, Unamortized Discount				80,000
Deferred Fees From Issuance Of Note				$ 28,000
Warrants Issued With cashless exercise during period		50,000
OR21 LLC [Member]
Basis Of Presentation [Line Items]
Equity Method Investment, Ownership Percentage		50.00%
Architectural Design Company [Member]
Basis Of Presentation [Line Items]
Equity Method Investment, Ownership Percentage		50.00%
Mevion Medical Systems Inc [Member]
Basis Of Presentation [Line Items]
Repayments of Notes Payable	$ 1,000,000

Per Share Amounts (Details)

Per Share Amounts (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Net income attributable to American Shared Hospital Services	$ 293,000	$ 51,000
Weighted average common shares for basic earnings per share	5,685,000	5,541,000
Diluted effect of stock options and restricted stock	199,000	0
Weighted average common shares for diluted earnings per share	5,884,000	5,541,000
Basic earnings per share	$ 0.05	$ 0.01
Diluted earnings per share	$ 0.05	$ 0.01

Per Share Amounts (Details Text

Per Share Amounts (Details Textual) - shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	617,000

Stock-based Compensation (Detai

Stock-based Compensation (Details) - Restricted Stock Units (RSUs) [Member]	3 Months Ended
	Mar. 31, 2017USD ($)$ / sharesshares
Shareholders Equity [Line Items]
Number of Options, Outstanding Beginning Balance | shares	4,000
Number of Options, Granted | shares	18,000
Number of Options, Vested | shares	(4,000)
Number of Options, Forfeited | shares	0
Number of Options, Outstanding Ending Balance | shares	18,000
Weighted Average Grant-Date Fair Value, Outstanding Beginning Balance | $ / shares	$ 2.25
Weighted Average Grant-Date Fair Value, Granted | $ / shares	3.40
Weighted Average Grant-Date Fair Value, Vested | $ / shares	3.40
Weighted Average Grant-Date Fair Value, Forfeited | $ / shares	0
Weighted Average Grant-Date Fair Value, Outstanding Ending Balance | $ / shares	$ 3.21
Intrinsic Value, Outstanding, Outstanding Beginning Balance | $	$ 0
Intrinsic Value, Granted | $	0
Intrinsic Value, Vested | $	0
Intrinsic Value, Forfeited | $	0
Intrinsic Value, Outstanding, Outstanding Ending Balance | $	$ 20,000

Stock-based Compensation (Det21

Stock-based Compensation (Details 1) - Employee Stock Option [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Schedule Of Share Based Compensation Stock Options Activity [Line Items]
Number of Options, Beginning balance	625,000
Number of Options, Granted	0
Stock Options, Exercised	(2,000)
Stock Options, Forfeited	0
Number of Options, Ending balance	623,000	625,000
Stock Options, Exercisable	304,000
Weighted Average Exercise Price, Beginning balance	$ 2.85
Weighted Average Exercise Price, Granted	0
Weighted Average Exercise Price, Exercised	2.81
Weighted Average Exercise Price, Forfeited	0
Weighted Average Exercise Price, Ending balance	2.85	$ 2.85
Grant Date Weighted Average Exercise Price, Exercisable	$ 2.83
Weighted Average Remaining Contractual Life (Years), Balance	4 years 7 days	4 years 3 months
Weighted Average Remaining Contractual Life (Years), Exercisable	3 years 9 months 18 days

Stock-based Compensation (Det22

Stock-based Compensation (Details Textual) - USD ($)	Jan. 04, 2017	Mar. 31, 2017	Mar. 31, 2016	Jun. 30, 2010
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share Based Compensation Expense		$ 50,000	$ 59,000
Incentive Compensation Plan [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance				1,630,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		356,000
Performance Share Award Agreement [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		$ 542,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	161,766

Investment in Equity Securiti23

Investment in Equity Securities (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Schedule of Cost-method Investments [Line Items]
Cost Method Investments	$ 579	$ 579
Mevion Medical Systems Inc [Member]
Schedule of Cost-method Investments [Line Items]
Cost Method Investments	$ 579,000
Cost Method Investments Ownership Percentage	0.46%

Fair Value of Financial Instr24

Fair Value of Financial Instruments (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Assets, Carrying Value:
Cash, cash equivalents, restricted cash, Carrying Value	$ 2,653	$ 3,121
Investment in equity securities, Carrying Value	579	579
Total, Carrying Value	3,232	3,700
Liabilities, Carrying Value
Debt obligations, Carrying Value	7,812	7,311
Total, Carrying Value	7,812	7,311
Assets, Fair Value:
Cash, cash equivalents, restricted cash, Fair Value	2,653	3,121
Investment in equity securities, Fair Value	579	579
Total, Fair Value	3,232	3,700
Liabilities, Fair Value
Debt obligations, Fair Value	7,040	7,354
Total, Fair Value	7,040	7,354
Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value:
Cash, cash equivalents, restricted cash, Fair Value	2,653	3,121
Investment in equity securities, Fair Value	0	0
Total, Fair Value	2,653	3,121
Liabilities, Fair Value
Debt obligations, Fair Value	0	0
Total, Fair Value	0	0
Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value:
Cash, cash equivalents, restricted cash, Fair Value	0	0
Investment in equity securities, Fair Value	0	0
Total, Fair Value	0	0
Liabilities, Fair Value
Debt obligations, Fair Value	0	0
Total, Fair Value	0	0
Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value:
Cash, cash equivalents, restricted cash, Fair Value	0	0
Investment in equity securities, Fair Value	579	579
Total, Fair Value	579	579
Liabilities, Fair Value
Debt obligations, Fair Value	7,040	7,354
Total, Fair Value	$ 7,040	$ 7,354

Repurchase of Common Stock (Det

Repurchase of Common Stock (Details Textual) - shares	Mar. 31, 2017	Dec. 31, 2008
Equity, Class of Treasury Stock [Line Items]
Stock Repurchase Program, Number of Shares Authorized to be Repurchased		1,000,000
Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased	72,000